Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingming Zhang

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
Journal of Thoracic Disease|June 16, 2023
Analysis of real-world data to investigate evolving treatment sequencing patterns in advanced non-small cell lung cancers and their impact on survivalZongzhi Liu, Kyeryoung Lee, David Cohn, et al.
Annals of Translational Medicine|April 3, 2023
The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancerZhipeng Wang, Haoyang Liu, Jinge Zhao, et al.
The Oncologist|September 6, 2022
Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate CancerSha Zhu, Yuchao Ni, Zilin Wang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 14, 2024
Integration Analysis of Single-Cell Multi-Omics Reveals Prostate Cancer HeterogeneityXiaojie Bian, Wenfeng Wang, Mierxiati Abudurexiti, et al.
Oncotarget|September 15, 2017
The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapyJinge Zhao, Pengfei Shen, Guangxi Sun, et al.
Asian Journal of Surgery|November 14, 2022
The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancerJinge Zhao, Guangxi Sun, Fengnian Zhao, et al.
European Journal of Medical Research|July 20, 2024
Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinomaJunjie Zhao, Xiuyi Pan, Zilin Wang, et al.
Cell Death & Disease|April 15, 2021
Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinibYang Cao, Huizhuang Shan, Meng Liu, et al.
The Prostate|August 22, 2019
Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?Tao Wu, Jinge Zhao, Zhenhua Liu, et al.
The Prostate|April 29, 2015
The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancerZhibin Chen, Ni Chen, Pengfei Shen, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Journal of Thoracic Disease|June 16, 2023
Analysis of real-world data to investigate evolving treatment sequencing patterns in advanced non-small cell lung cancers and their impact on survivalZongzhi Liu, Kyeryoung Lee, David Cohn, et al.
Annals of Translational Medicine|April 3, 2023
The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancerZhipeng Wang, Haoyang Liu, Jinge Zhao, et al.
The Oncologist|September 6, 2022
Plasma Exosomal AKR1C3 mRNA Expression Is a Predictive and Prognostic Biomarker in Patients with Metastatic Castration-Resistant Prostate CancerSha Zhu, Yuchao Ni, Zilin Wang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|March 14, 2024
Integration Analysis of Single-Cell Multi-Omics Reveals Prostate Cancer HeterogeneityXiaojie Bian, Wenfeng Wang, Mierxiati Abudurexiti, et al.
Oncotarget|September 15, 2017
The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapyJinge Zhao, Pengfei Shen, Guangxi Sun, et al.
Asian Journal of Surgery|November 14, 2022
The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with different pathological patterns of prostate cancerJinge Zhao, Guangxi Sun, Fengnian Zhao, et al.
European Journal of Medical Research|July 20, 2024
Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinomaJunjie Zhao, Xiuyi Pan, Zilin Wang, et al.
Cell Death & Disease|April 15, 2021
Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinibYang Cao, Huizhuang Shan, Meng Liu, et al.
The Prostate|August 22, 2019
Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?Tao Wu, Jinge Zhao, Zhenhua Liu, et al.
The Prostate|April 29, 2015
The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancerZhibin Chen, Ni Chen, Pengfei Shen, et al.
Pageof 13